FDA Student Research Opportunity in Regenerative Medicine
*Applications will be reviewed on a rolling-basis.
A research opportunity is currently available with the Office of Tissues and Advanced Therapies (OTAT), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
CBER’s mission is to ensure the safety, purity, potency, and effectiveness of biological products including vaccines, blood and blood products, and cells, tissues, and gene therapies for the prevention, diagnosis, and treatment of human diseases, conditions, or injury. Under the guidance of a mentor, the selected participant will have the opportunity to receive training on how practical microsystems would be used in the assessment of regenerative medicine advanced therapeutic products such as cellular and tissue engineered products. The project will employ a variety of approaches including Microfluidics, Biomaterials engineering, Cell Culture, High-resolution imaging, and Molecular biology.
Anticipated Appointment Start Date: May 1, 2020
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is part-time (20 hours per week) at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Qualifications
The qualified candidate should be currently pursuing a bachelor's degree in one of the relevant fields.
This opportunity is available to US citizens and Lawful Permanent Residents only.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2020-0026) in your email.